Pemvidutide: Reference Overview and Reconstitution Notes

Pemvidutide

What it is

Pemvidutide, also referenced by the development code ALT-801, is a synthetic, lipidated peptide that acts as a balanced dual agonist at both the GLP-1 receptor and the glucagon receptor. It is being developed by Altimmune and belongs to the broader family of incretin-based, multi-receptor metabolic peptides.

Research context and categorization

Pemvidutide is grouped under the metabolic and weight-regulation category of compounds. Its two receptor targets are described as complementary: GLP-1 receptor activity is commonly discussed in relation to appetite signaling and glucose handling, while glucagon receptor activity is commonly discussed in relation to energy expenditure and hepatic lipid metabolism.

In published and reported studies, pemvidutide has been investigated for its effects on body weight and on liver fat content, and it has been evaluated in trials focused on metabolic dysfunction-associated steatohepatitis (MASH) and on obesity. It has also been examined in the context of alcohol use disorder. All of these uses are investigational. Pemvidutide is not FDA-approved for any indication, and the effects reported in trials should be understood as research findings still under evaluation rather than confirmed or approved benefits.

Status

  • Regulatory status: Research-only and investigational. Not FDA-approved for any indication. As of 2026 it has received FDA Fast Track designation and Breakthrough Therapy Designation for MASH, which are regulatory pathway designations and not approvals, and it has been reported as advancing toward Phase 3 evaluation.
  • Sport status: Not specifically listed by name on the WADA Prohibited List. GLP-1 and glucagon receptor agonist peptides are commonly discussed in relation to the S2 (peptide hormones, growth factors, related substances, and mimetics) and S4 (hormone and metabolic modulators) categories, and this area has been under active review, so status can change. Anyone subject to anti-doping rules should confirm the current WADA guidance directly.

Reconstitution notes (general)

Pemvidutide is typically supplied as a lyophilized (freeze-dried) powder that is reconstituted before use. Concentration is determined by a simple relationship: concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, adding 2 mL of bacteriostatic water to a 10 mg vial yields a concentration of 5 mg/mL. To work out concentration and measured volumes for a given vial, use the calculator at our reconstitution and blend calculators.

Dilution and handling notes (compound-specific)

Pemvidutide is a lyophilized peptide, so it does require reconstitution rather than arriving as a ready-to-use liquid. Bacteriostatic water is generally preferred over plain sterile water for vials that will be accessed more than once, because the small amount of benzyl alcohol it contains acts as a preservative across a multi-week refrigerated window. Research vials are commonly encountered in the single-digit to low-tens of milligrams range, and 1 mL to 2 mL of bacteriostatic water per vial is a typical starting point, chosen mainly to land on a convenient concentration.

The compound-specific quirk worth knowing is that pemvidutide is a lipidated peptide. Its structure carries a fatty-acid moiety (part of an albumin-binding EuPort domain) that promotes self-association. Lipidated GLP-1-class peptides of this type tend to associate into larger aggregates and can turn viscous, gel, cloud, or leave a hazy film when pushed to high concentrations, more so than a plain unmodified peptide at the same milligrams per millilitre. The practical consequence is to lean toward more diluent rather than less: a larger water volume that keeps the concentration modest usually gives a clearer, easier-to-handle solution and reduces the chance of gelling.

Handling technique matters for the same reason. Allow both the powder vial and the bacteriostatic water to reach room temperature first, then add the water slowly down the inner wall of the vial rather than jetting it onto the powder. Let the vial sit and swirl it gently in slow circles instead of shaking, because the surfactant-like lipid tail makes these solutions foam readily, and foam traps material and slows full dissolution. Full dissolution can take a few minutes of patient swirling. A solution that stays cloudy or gelled after it has had time to dissolve, or that will not clear on gentle swirling, should not be used.

Handling and storage

Store the reconstituted solution refrigerated at 2 to 8 C and out of direct light. Wipe the vial stopper with an alcohol swab before each access, and label the vial with the mix date so the refrigerated window can be tracked. A reconstituted vial is commonly treated as usable for roughly four weeks when kept cold, though this is a conservative reference guideline rather than a fixed rule. Discard the solution if it becomes cloudy or discolored, or if any floating particles appear.

Related reading

Tools and supplies

For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.